The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …

Targeting cancer with small molecule irreversible inhibitors of kinases represents an
emerging challenge in drug discovery. Irreversible inhibitors bind to kinase active site in a …

MicroRNAs (miRNAs) are emerging as important modulators in cellular pathways and they
appear to play a key role in tumorigenesis. MiR-145 is downregulated in several human …

Purpose: To evaluate the efficacy and safety of gefitinib plus simvastatin (GS) versus
gefitinib alone (G) in previously treated patients with advanced non–small cell lung cancer …

Immunohistochemistry (IHC) is a well-established and commonly used staining method for
clinical diagnosis and biomedical research. In most IHC images, the target protein is …

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2
(VEGFR2) have emerged as two effective clinical targets for non-small-cell lung cancer …

Background Although the alterations of lipid profile in lung cancer have been documented,
the prognostic value of serum HDL-C level and its correlation with inflammation in NSCLC …

Radioresistance has been an important factor in restricting efficacy of radiotherapy for non-
small cell lung cancer (NSCLC) patients and new approaches to inhibit cancer growth and …

Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do
not have activating mutations in the tyrosine kinase domain of the epidermal growth factor …

Brain metastases are not only the most common intracranial neoplasm in adults but also
very prevalent in patients with lung cancer. Patients have been grouped into different …